Ji Qingwei, Lin Yingzhong, Liang Zhishan, Yu Kunwu, Liu Yuyang, Fang Zhe, Liu Ling, Shi Ying, Zeng Qiutang, Chang Chao, Chai Meng, Zhou Yujie
Cardiovasc Diabetol. 2014 Nov 1;13:145. doi: 10.1186/s12933-014-0145-4.
Recent evidence demonstrated that the circulating adipokines were associated with the onset of acute coronary syndrome (ACS) including unstable angina pectoris (UAP) and acute myocardial infarction (AMI). As a novel adipokine, chemerin has been related to atherosclerosis and the presence of coronary artery disease. However, the plasma levels of chemerin in patients with ACS have yet to be investigated.
Plasma levels of chemerin and adiponectin were measured by an enzyme-linked immunosorbent assay (ELISA) in 60 patients with stable angina pectoris (SAP), 60 patients with UAP, 60 patients with AMI and 40 control patients. Left ventricular end-diastolic diameter (LVEDD) and left ventricular ejection fraction (LVEF) were measured using a GE ViVid E7 ultrasonography machine, and the severity of coronary stenosis in patients was estimated with a Gensini coronary score following coronary angiography.
Plasma chemerin levels were significantly higher in ACS patients than in the control and SAP groups, while plasma adiponectin levels were significantly lower in ACS patients than the control group. A correlation analysis revealed that plasma chemerin levels were positively correlated with the levels of C-reactive protein (CRP) (r = 0.29, P < 0.01) and LVEDD (r = 0.27, P < 0.01) but negatively correlated with LVEF (r = -0.45, P < 0.01) and that plasma adiponectin levels were positively correlated with LVEF (r = 0.53, P < 0.01) but negatively correlated with CRP (r = -0.33, P < 0.01) and LVEDD (r = -0.30, P < 0.01). Although significant correlations between chemerin, adiponectin and BMI or the Gensini coronary score were found in patients with SAP, neither chemerin nor adiponectin was correlated with BMI and the Gensini coronary score in patients with ACS. Furthermore, both chemerin (OR 1.103, 95% CI 1.065 to 1.142; P = 0.001) and adiponectin (OR 0.871, 95% CI 0.776 to 0.970; P = 0.018) were independently associated with the presence of ACS.
Chemerin is a novel biomarker of acute coronary syndrome but not of stable angina pectoris.
最近有证据表明，循环中的脂肪因子与急性冠状动脉综合征（ACS）的发病有关，包括不稳定型心绞痛（UAP）和急性心肌梗死（AMI）。作为一种新型脂肪因子，趋化素已被证明与动脉粥样硬化和冠状动脉疾病的存在有关。然而，ACS患者血浆中趋化素的水平尚未得到研究。
采用酶联免疫吸附测定（ELISA）法检测60例稳定型心绞痛（SAP）患者、60例UAP患者、60例AMI患者和40例对照患者血浆中趋化素和脂联素的水平。使用GE ViVid E7超声心动图仪测量左心室舒张末期内径（LVEDD）和左心室射血分数（LVEF），并在冠状动脉造影后用Gensini冠状动脉评分评估患者冠状动脉狭窄的严重程度。
ACS患者血浆趋化素水平显著高于对照组和SAP组，而ACS患者血浆脂联素水平显著低于对照组。相关性分析显示，血浆趋化素水平与C反应蛋白（CRP）水平呈正相关（r = 0.29，P < 0.01），与LVEDD呈正相关（r = 0.27，P < 0.01），但与LVEF呈负相关（r = -0.45，P < 0.01）；血浆脂联素水平与LVEF呈正相关（r = 0.53，P < 0.01），但与CRP呈负相关（r = -0.33，P < 0.01），与LVEDD呈负相关（r = -0.30，P < 0.01）。虽然在SAP患者中发现趋化素、脂联素与BMI或Gensini冠状动脉评分之间存在显著相关性，但在ACS患者中，趋化素和脂联素均与BMI和Gensini冠状动脉评分无关。此外，趋化素（OR 1.103，95% CI 1.065至1.142；P = 0.001）和脂联素（OR 0.871，95% CI 0.776至0.970；P = 0.018）均与ACS的存在独立相关。
趋化素是急性冠状动脉综合征的一种新型生物标志物，但不是稳定型心绞痛的生物标志物。
